NR1I2 Receptor: A Promising Drug Target for Neurodegenerative Diseases

Target Name: NR1I2

NCBI ID: G8856

NR1I2

NR1I2 Receptor: A Promising Drug Target for Neurodegenerative Diseases

The NR1I2 (neuron-restoring receptor 1, type 2) is a protein that is expressed in various tissues of the body, including the brain, spinal cord, and peripheral nerves. It is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a crucial role in cellular signaling.

The NR1I2 receptor is involved in a wide range of physiological processes in the body, including neuronal function and development, neurotransmitter signaling, and pain perception. It is thought to play a key role in the regulation of neural stem/progenitor cells (NSPCs), which are cells that have the ability to give rise to a variety of different neural cell types.

One of the most promising aspects of the NR1I2 receptor is its potential as a drug target. The use of steroids and xenobiotics, which are molecules that mimic the activity of hormones, has been shown to stimulate the NR1I2 receptor and to improve neuronal function in a variety of experimental models of neurodegenerative diseases.

Steroids, such as testosterone and androstenedione, are well-established regulators of cellular signaling, and have been shown to play a key role in the regulation of neuronal function. Xenobiotics, such as the chemotherapy drug doxorubicin, have also been shown to stimulate the NR1I2 receptor and to improve neuronal function in cancer cells.

The NR1I2 receptor is also an attractive biomarker for tracking the effectiveness of therapeutic treatments for neurodegenerative diseases. For example, the use of doxorubicin, a xenobiotic drug, has been shown to improve the expression of the NR1I2 receptor in primary astrocytes, which are a type of brain cell, and to increase the number of neurons that are labeled with the protein.

In addition to its potential as a drug target and biomarker, the NR1I2 receptor is also of interest as a potential therapeutic target for a variety of neurodegenerative diseases. For example, theNR1I2 receptor has been shown to be involved in the regulation of neurotransmitter release from neurons, which may be important in the pathophysiology of a wide range of neurodegenerative diseases.

Overall, the NR1I2 receptor is a complex and well-researched protein that is of great interest to researchers as a potential drug target and biomarker for a variety of neurodegenerative diseases. Further studies are needed to fully understand the role of the NR1I2 receptor in cellular signaling and to develop effective therapies based on this protein.

Protein Name: Nuclear Receptor Subfamily 1 Group I Member 2

Functions: Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes

The "NR1I2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR1I2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets